This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tréluyer, J.-M.
Right arrow Articles by Dupin, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tréluyer, J.-M.
Right arrow Articles by Dupin, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2002, p. 4009-4012, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.4009-4012.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

High Concentrations of Nelfinavir as an Independent Risk Factor for Lipodystrophy in Human Immunodeficiency Virus-Infected Patients

Jean-Marc Tréluyer,1* Jean-Pierre Morini,2 Jérome Dimet,1 Isabelle Gorin,2 Elisabeth Rey,1 Jean Deleuze,2 Pierre-François Ceccaldi,1 Jean-Paul Escande,2 Gérard Pons,1 and Nicolas Dupin2

Pharmacologie Périnatale et Pédiatrique,1 Dermatologie-Vénérologie, Groupe Hospitalier Cochin-Saint Vincent de Paul (AP-HP), Université René Descartes, 75674 Paris Cedex 14, France2

Received 26 February 2002/ Returned for modification 14 May 2002/ Accepted 27 August 2002

To assess the relationship between antiretroviral drug exposure and lipodystrophy, 69 human immunodeficiency virus type 1-infected patients receiving nelfinavir were investigated cross-sectionally. Lipodystrophy was defined by patients' self-report. Nelfinavir trough concentrations in plasma were significantly related to overall lipodystrophy and peripheral fat wasting scores and appeared to be an independent risk factor for lipodystrophy

* Corresponding author. Mailing address: Pharmacologie, Groupe Hospitalier Cochin-Saint Vincent de Paul (AP-HP), 82 avenue Denfert Rochereau, 75674 Paris Cedex 14, France. Phone: 33 1 01 40 48 82 12. Fax: 33 1 01 40 48 83 27/28. E-mail: jm.treluyer{at}svp.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, December 2002, p. 4009-4012, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.4009-4012.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hirt, D., Treluyer, J.-M., Jullien, V., Firtion, G., Chappuy, H., Rey, E., Pons, G., Mandelbrot, L., Urien, S. (2006). Pregnancy-related effects on nelfinavir-m8 pharmacokinetics: a population study with 133 women.. Antimicrob. Agents Chemother. 50: 2079-2086 [Abstract] [Full Text]  
  • Hirt, D., Urien, S., Jullien, V., Firtion, G., Rey, E., Pons, G., Blanche, S., Treluyer, J.-M. (2006). Age-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children. Antimicrob. Agents Chemother. 50: 910-916 [Abstract] [Full Text]  
  • Regazzi, M., Maserati, R., Villani, P., Cusato, M., Zucchi, P., Briganti, E., Roda, R., Sacchelli, L., Gatti, F., Delle Foglie, P., Nardini, G., Fabris, P., Mori, F., Castelli, P., Testa, L. (2005). Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected Subjects. Antimicrob. Agents Chemother. 49: 643-649 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»